Skip to main content Back to Top
Advertisement

8/22/2019

Sodium Polystyrene Sulfonate Oral or Rectal Suspension

Products Affected - Description

    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 120 mL contains sorbitol bottle, NDC 46287-0006-04
    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 473 mL contains sorbitol bottle, NDC 46287-0006-01
    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 60 mL contains sorbitol bottle, 10 count, NDC 46287-0006-60
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 120 mL bottle, NDC 00054-0379-50
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 500 mL bottle, NDC 00054-0379-63 - discontinued
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 60 mL bottle, 10 count, NDC 00054-0379-51

Reason for the Shortage

    • CMP Pharma reports that increased demand has led to a shortage of raw material required to manufacture the products. They are using available powder to manufacture the suspension.
    • Perrigo has temporarily discontinued their Kionex suspension and sodium polystyrene sulfonate (sorbitol-free) suspension. They cannot estimate when these products will be manufactured again.
    • Hikma is not currently marketing sodium polystyrene sulfonate suspension.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • CMP Pharma has SPS Suspension on allocation and the company is shipping supplies regularly.

Implications for Patient Care

    • Other potassium binders include patiromer (Veltassa; Relypsa) and sodium zirconium cyclosilicate (Lokelma; AstraZeneca). FDA approved Lokelma in May 2018, but AstraZeneca estimates that it will not be available for purchase until early 2019.

Updated

Updated August 22, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created June 4, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins